These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26378953)

  • 101. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.
    Velders MA; Abtan J; Angiolillo DJ; Ardissino D; Harrington RA; Hellkamp A; Himmelmann A; Husted S; Katus HA; Meier B; Schulte PJ; Storey RF; Wallentin L; Gabriel Steg P; James SK;
    Heart; 2016 Apr; 102(8):617-25. PubMed ID: 26848185
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study.
    Chandrasekhar J; Baber U; Sartori S; Faggioni M; Aquino M; Kini A; Weintraub W; Rao S; Kapadia S; Weiss S; Strauss C; Toma C; Muhlestein B; DeFranco A; Effron M; Keller S; Baker B; Pocock S; Henry T; Mehran R
    Catheter Cardiovasc Interv; 2017 Mar; 89(4):629-637. PubMed ID: 27152497
    [TBL] [Abstract][Full Text] [Related]  

  • 103. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.
    Dörler J; Edlinger M; Alber HF; Altenberger J; Benzer W; Grimm G; Huber K; Pachinger O; Schuchlenz H; Siostrzonek P; Zenker G; Weidinger F;
    Eur Heart J; 2011 Dec; 32(23):2954-61. PubMed ID: 21920970
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
    Mrdovic I; Savic L; Krljanac G; Asanin M; Cvetinovic N; Brdar N; Stojanovic M; Djuricic N; Stankovic S; Marinkovic J; Perunicic J
    J Interv Cardiol; 2013 Jun; 26(3):221-7. PubMed ID: 23373620
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    Sabatine MS; Cannon CP; Gibson CM; López-Sendón JL; Montalescot G; Theroux P; Claeys MJ; Cools F; Hill KA; Skene AM; McCabe CH; Braunwald E;
    N Engl J Med; 2005 Mar; 352(12):1179-89. PubMed ID: 15758000
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-.
    Vavuranakis M; Vrachatis DA; Papaioannou TG; Archontakis S; Kalogeras KI; Kariori MG; Gafou A; Moldovan C; Tzamalis P; Stefanadis C
    Circ J; 2011; 75(9):2105-12. PubMed ID: 21712606
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Effect of Hematologic Parameters on Microvascular Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention.
    Karahan Z; Uçaman B; Uluğ AV; Aydınalp Ö; Uğurlu M; Çevik K; Kaya İ; Öztürk Ö
    Angiology; 2016 Feb; 67(2):151-6. PubMed ID: 26007233
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Prehospital Prasugrel Versus Ticagrelor in Real-World Patients With ST-Elevation Myocardial Infarction Referred for Primary PCI: Procedural and 30-Day Outcomes.
    Vos NS; Amoroso G; Vink MA; Maarse M; Adams R; Herrman JR; Patterson MS; van der Schaaf RJ; Slagboom T; de Winter RJ
    J Invasive Cardiol; 2018 Dec; 30(12):431-436. PubMed ID: 30318484
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
    Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
    [TBL] [Abstract][Full Text] [Related]  

  • 111. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
    Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E
    Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction.
    Silvain J; Rakowski T; Lattuca B; Liu Z; Bolognese L; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimsky P; Miller D; Portal JJ; Collet JP; Vicaut E; Montalescot G; Dudek D;
    J Am Coll Cardiol; 2019 Mar; 73(8):906-914. PubMed ID: 30819358
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Prasugrel versus clopidogrel for residual thrombus burden in patients with ST-segment elevation myocardial infarction: an optical coherence tomography study.
    Yokota T; Higuma T; Endo T; Nishizaki F; Hanada K; Yokoyama H; Yamada M; Okumura K; Tomita H
    Coron Artery Dis; 2018 Dec; 29(8):663-669. PubMed ID: 30308586
    [TBL] [Abstract][Full Text] [Related]  

  • 116. A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study.
    So DY; Wells GA; McPherson R; Labinaz M; Le May MR; Glover C; Dick AJ; Froeschl M; Marquis JF; Gollob MH; Tran L; Bernick J; Hibbert B; Roberts JD
    Pharmacogenomics J; 2016 Feb; 16(1):71-8. PubMed ID: 25850030
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry.
    De Filippo O; Cortese M; D Ascenzo F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Montefusco A; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Rinaldi M
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):381-391. PubMed ID: 31030413
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).
    Bacquelin R; Oger E; Filippi E; Hacot JP; Auffret V; Le Guellec M; Coudert I; Castellant P; Moquet B; Druelles P; Rialan A; Rouault G; Boulanger B; Treuil J; Leurent G; Bedossa M; Boulmier D; Avez B; Gilard M; Le Breton H
    Arch Cardiovasc Dis; 2016 Jan; 109(1):31-8. PubMed ID: 26514325
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial.
    Ottani F; Femia EA; Cattaneo M; Caravita L; Attanasio C; Galvani M
    Int J Cardiol; 2018 Mar; 255():8-14. PubMed ID: 29336914
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Capranzano P; Capodanno D; Bucciarelli-Ducci C; Gargiulo G; Tamburino C; Francaviglia B; Ohno Y; La Manna A; Antonella S; Attizzani GF; Angiolillo DJ; Tamburino C
    Eur Heart J Acute Cardiovasc Care; 2016 Sep; 5(5):475-86. PubMed ID: 26758542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.